Week of May 21, 2012: FDA Approves BMS's New Bulk Biologics Manufacturing Facility; SGS Acquires Vitrology; and More - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Week of May 21, 2012: FDA Approves BMS's New Bulk Biologics Manufacturing Facility; SGS Acquires Vitrology; and More

ePT--the Electronic Newsletter of Pharmaceutical Technology

Bristol-Myers Squibb received FDA approval for its new bulk biologics manufacturing facility in Devens, Massachusetts, for commercial production of Orencia (abatacept). Construction of the Devens facility began in early 2007 and was subsequently completed in 2010. The company submitted the site for regulatory approval in early 2012. Read More

EQT, a Sweden-based private equity group, and Agilent Technologies have agreed to acquire Dako, a Denmark-based diagnostic company, for $2.2 billion. Dako provides antibodies, reagents, scientific instruments and software primarily to pathology laboratories for cancer diagnostics. Dako also collaborates with pharmaceutical companies to develop pharmacodiagnostics or companion diagnostics, which may be used to identify patients most likely to benefit from a specific targeted therapy. The acquisition is expected to close within the next two months and is subject to the satisfaction of customary closing conditions. Read More

SGS has acquired Vitrology, a biopharmaceutical contract testing organization specializing in virology, cell and molecular biology, microbiology, and electron microscopy. The acquisition expands SGS’s Life Science Services global network to 19 laboratories. Read More

Industry Briefs:

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here